These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 20619386)

  • 21. De novo mutations in CBL causing early-onset paediatric moyamoya angiopathy.
    Guey S; Grangeon L; Brunelle F; Bergametti F; Amiel J; Lyonnet S; Delaforge A; Arnould M; Desnous B; Bellesme C; Hervé D; Schwitalla JC; Kraemer M; Tournier-Lasserve E; Kossorotoff M
    J Med Genet; 2017 Aug; 54(8):550-557. PubMed ID: 28343148
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A case of splenomegaly in CBL syndrome.
    Coe RR; McKinnon ML; Tarailo-Graovac M; Ross CJ; Wasserman WW; Friedman JM; Rogers PC; van Karnebeek CDM
    Eur J Med Genet; 2017 Jul; 60(7):374-379. PubMed ID: 28414188
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Embryonal rhabdomyosarcoma in a patient with a germline CBL pathogenic variant.
    Ji J; Navid F; Hiemenz MC; Kaneko M; Zhou S; Saitta SC; Biegel JA
    Cancer Genet; 2019 Feb; 231-232():62-66. PubMed ID: 30803559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Craniosynostosis in patients with Noonan syndrome caused by germline KRAS mutations.
    Kratz CP; Zampino G; Kriek M; Kant SG; Leoni C; Pantaleoni F; Oudesluys-Murphy AM; Di Rocco C; Kloska SP; Tartaglia M; Zenker M
    Am J Med Genet A; 2009 May; 149A(5):1036-40. PubMed ID: 19396835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Determinants of the Gain-of-Function Phenotype of Human Leukemia-associated Mutant CBL Oncogene.
    Nadeau SA; An W; Mohapatra BC; Mushtaq I; Bielecki TA; Luan H; Zutshi N; Ahmad G; Storck MD; Sanada M; Ogawa S; Band V; Band H
    J Biol Chem; 2017 Mar; 292(9):3666-3682. PubMed ID: 28082680
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Novel oncogenic mutations of CBL in human acute myeloid leukemia that activate growth and survival pathways depend on increased metabolism.
    Fernandes MS; Reddy MM; Croteau NJ; Walz C; Weisbach H; Podar K; Band H; Carroll M; Reiter A; Larson RA; Salgia R; Griffin JD; Sattler M
    J Biol Chem; 2010 Oct; 285(42):32596-605. PubMed ID: 20622007
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydrops, fetal pleural effusions and chylothorax in three patients with CBL mutations.
    Bülow L; Lissewski C; Bressel R; Rauch A; Stark Z; Zenker M; Bartsch O
    Am J Med Genet A; 2015 Feb; 167A(2):394-9. PubMed ID: 25358541
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Two cases of Noonan syndrome with severe respiratory and gastroenteral involvement and the SOS1 mutation F623I.
    Fabretto A; Kutsche K; Harmsen MB; Demarini S; Gasparini P; Fertz MC; Zenker M
    Eur J Med Genet; 2010; 53(5):322-4. PubMed ID: 20673819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expansion of the genotypic and phenotypic spectrum in patients with KRAS germline mutations.
    Zenker M; Lehmann K; Schulz AL; Barth H; Hansmann D; Koenig R; Korinthenberg R; Kreiss-Nachtsheim M; Meinecke P; Morlot S; Mundlos S; Quante AS; Raskin S; Schnabel D; Wehner LE; Kratz CP; Horn D; Kutsche K
    J Med Genet; 2007 Feb; 44(2):131-5. PubMed ID: 17056636
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.
    Nava C; Hanna N; Michot C; Pereira S; Pouvreau N; Niihori T; Aoki Y; Matsubara Y; Arveiler B; Lacombe D; Pasmant E; Parfait B; Baumann C; Héron D; Sigaudy S; Toutain A; Rio M; Goldenberg A; Leheup B; Verloes A; Cavé H
    J Med Genet; 2007 Dec; 44(12):763-71. PubMed ID: 17704260
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H; Cazzolli H; Szpurka H; Dunbar A; Tiu R; Huh J; Muramatsu H; O'Keefe C; Hsi E; Paquette RL; Kojima S; List AF; Sekeres MA; McDevitt MA; Maciejewski JP
    J Clin Oncol; 2009 Dec; 27(36):6109-16. PubMed ID: 19901108
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Noonan syndrome: clinical aspects and molecular pathogenesis.
    Tartaglia M; Zampino G; Gelb BD
    Mol Syndromol; 2010 Feb; 1(1):2-26. PubMed ID: 20648242
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Co-occurring SHOC2 and PTPN11 mutations in a patient with severe/complex Noonan syndrome-like phenotype.
    Ekvall S; Hagenäs L; Allanson J; Annerén G; Bondeson ML
    Am J Med Genet A; 2011 Jun; 155A(6):1217-24. PubMed ID: 21548061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome.
    Aoki Y; Niihori T; Banjo T; Okamoto N; Mizuno S; Kurosawa K; Ogata T; Takada F; Yano M; Ando T; Hoshika T; Barnett C; Ohashi H; Kawame H; Hasegawa T; Okutani T; Nagashima T; Hasegawa S; Funayama R; Nagashima T; Nakayama K; Inoue S; Watanabe Y; Ogura T; Matsubara Y
    Am J Hum Genet; 2013 Jul; 93(1):173-80. PubMed ID: 23791108
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis.
    Flex E; Jaiswal M; Pantaleoni F; Martinelli S; Strullu M; Fansa EK; Caye A; De Luca A; Lepri F; Dvorsky R; Pannone L; Paolacci S; Zhang SC; Fodale V; Bocchinfuso G; Rossi C; Burkitt-Wright EM; Farrotti A; Stellacci E; Cecchetti S; Ferese R; Bottero L; Castro S; Fenneteau O; Brethon B; Sanchez M; Roberts AE; Yntema HG; Van Der Burgt I; Cianci P; Bondeson ML; Cristina Digilio M; Zampino G; Kerr B; Aoki Y; Loh ML; Palleschi A; Di Schiavi E; Carè A; Selicorni A; Dallapiccola B; Cirstea IC; Stella L; Zenker M; Gelb BD; Cavé H; Ahmadian MR; Tartaglia M
    Hum Mol Genet; 2014 Aug; 23(16):4315-27. PubMed ID: 24705357
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutations of c-Cbl in myeloid malignancies.
    Katzav S; Schmitz ML
    Oncotarget; 2015 May; 6(13):10689-96. PubMed ID: 26028666
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Severe Noonan syndrome phenotype associated with a germline Q71R MRAS variant: a recurrent substitution in RAS homologs in various cancers.
    Suzuki H; Takenouchi T; Uehara T; Takasago S; Ihara S; Yoshihashi H; Kosaki K
    Am J Med Genet A; 2019 Aug; 179(8):1628-1630. PubMed ID: 31173466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular and clinical studies in 107 Noonan syndrome affected individuals with PTPN11 mutations.
    Athota JP; Bhat M; Nampoothiri S; Gowrishankar K; Narayanachar SG; Puttamallesh V; Farooque MO; Shetty S
    BMC Med Genet; 2020 Mar; 21(1):50. PubMed ID: 32164556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel association of neurofibromatosis type 1-causing mutations in families with neurofibromatosis-Noonan syndrome.
    Ekvall S; Sjörs K; Jonzon A; Vihinen M; Annerén G; Bondeson ML
    Am J Med Genet A; 2014 Mar; 164A(3):579-87. PubMed ID: 24357598
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Two novel germline KRAS mutations: expanding the molecular and clinical phenotype.
    Stark Z; Gillessen-Kaesbach G; Ryan MM; Cirstea IC; Gremer L; Ahmadian MR; Savarirayan R; Zenker M
    Clin Genet; 2012 Jun; 81(6):590-4. PubMed ID: 21797849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.